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The extracellular matrix protein fibulin-1 suppresses the motility and invasiveness of a variety of tumour cell types in vitro as well as
the growth of fibrosarcoma tumours in nude mice. In this study, fibulin-1 protein expression in breast carcinoma specimens and
normal breast tissue was evaluated immunohistologically. Fibulin-1 protein expression was also semiquantitatively assessed by
immunoblot analysis in a collection of normal breast tissues (n¼18), benign tumours (n¼5) and breast carcinomas (n¼39). In
normal breast tissue, fibulin-1 protein expression predominated in the ductal epithelium and underlying myoepithelium, with weaker
staining evident in the loose connective surrounding the ducts. Examination of breast carcinomas revealed that the tumour cells also
expressed fibulin-1 protein. The level of mature fibulin-1 polypeptide (100kDa) was higher in the breast carcinoma specimens as
compared to normal breast tissue (Mann–Whitney U-test, P¼0.0005). In addition to the mature fibulin-1 polypeptide, several
smaller sized polypeptides of 55, 50 and 25kDa were detected using monoclonal antibodies reactive towards an epitope located at
the N-terminus of fibulin-1. The immunoreactive 50kDa polypeptide was detected more frequently in breast carcinoma specimens
than in normal breast tissue (w
2¼17.22, Po0.0001). Furthermore, the ratio of the 50kDa fragment to the mature fibulin-1
polypeptide correlated with the level of oestrogen receptor a (Spearman correlation coefficient, rs¼0.49, Po0.003, n¼36) and
progesterone receptor (rs¼0.43, P¼0.008, n¼36) expression in the tumour specimens. Taken together, these findings indicate
that elevated expression and altered processing of fibulin-1 is associated with human breast cancer.
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Fibulin-1 is an extracellular matrix and plasma protein that has
been implicated as playing a role in tumour progression (Qing et al,
1997; Hayashido et al, 1998; Twal et al, 2001). Alternative splicing
of fibulin-1 precursor results in four transcript variants, desig-
nated A–D, of which C and D are predominantly expressed (Tran
et al, 1997). Overexpression of fibulin-1D in fibrosarcoma-derived
cells has been shown to delay tumour formation in nude mice and
suppress invasion into gels of reconstituted basement membrane
extracts (Qing et al, 1997). Furthermore, human placenta-derived
fibulin-1 protein has also been shown to inhibit cell adhesion,
spreading and motility of a range of human tumour cell lines,
including those originating from melanoma, epidermoid car-
cinoma and breast carcinoma (Twal et al, 2001). A recent study
showed increased fibulin-1C:1D mRNA ratios in ovarian carci-
nomas (Moll et al, 2002). Additionally, fibulin-1C expression is
induced by oestradiol in oestrogen receptor a (ERa)-positive
ovarian tumour cells (Clinton et al, 1996; Moll et al, 2002). These
results suggest that the biological function of fibulin-1 during
tumour progression may be variant-specific.
Despite there being substantial evidence for fibulin-1 having the
ability to influence tumour cell behaviour, there is a very limited
understanding of the expression of fibulin-1 protein in association
with human cancers. Indeed, there are only two reports to date
(both from the same research group) that document the expression
of fibulin-1 in human cancer, specifically ovarian carcinoma
(Roger et al, 1998; Moll et al, 2002). In this study, we evaluated
fibulin-1 protein expression in human breast tumours. We also
sought to correlate fibulin-1 expression levels with the oestrogen
receptor status of the breast tumour specimens.
MATERIALS AND METHODS
Handling of tumours
The breast tissue samples used in this study were obtained from
the Department of Surgery, St Vincent’s University Hospital,
Dublin and the Department of Pathology, Mater Private Hospital,
Dublin. Patient characteristics, including histological details and
steroid receptor status, are summarised in Table 1. ERa and
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yprogesterone receptor (PR) status of the breast tumours was
determined by cytosolic assays (Cullen et al, 2001). The cutoff
point for ERa and PR status was 200fmolg
 1. Normal breast tissue
specimens were obtained from sites either remote from the
primary tumour or from cosmetic reduction mammoplasties.
Immunohistochemistry
Tumour specimens were fixed in 3.7% paraformaldehyde for 24h,
embedded in paraffin wax and sectioned at 5mm thickness.
Sections were deparaffinised with xylene and graded ethanol,
followed by rehydration with phosphate-buffered saline (PBS) at
pH 7.3. Endogenous peroxidase activity was quenched by
incubating the sections with 3% hydrogen peroxide in PBS for
10min. Sections were subsequently washed with PBS and blocked
by incubation with 5% normal horse serum in PBS (blocking
solution A) for 20min at room temperature (RT). Sections were
then incubated with the mouse antifibulin-1 monoclonal antibody
(mAb) 3A11, diluted 1/500 (3mgml
 1) in blocking solution A, for
2h at RT. After washing with PBS, immunoglobulin G (IgG)
detection was performed with the Vectastain Elite ABC kit (Vector
Laboratories, Peterborough, UK) according to the manufacturer’s
recommendations. Staining was then visualised using 0.05%
3,3-diaminobenzidine/0.01% hydrogen peroxide (Vector Labora-
tories). Nuclei were counterstained using methyl green (Vector
Laboratories). Sections were then dehydrated and mounted in
distrene dibutylpthalate xylene. Immunostaining specificity was
checked using an irrelevant mouse mAb (UPC10; Sigma, Dorset,
UK) of the same immunoglobulin subclass (IgG2a) as the
antifibulin-1 mAb.
Immunoblot analysis
Breast tissue specimens were rapidly frozen in liquid nitrogen and
stored at  801C. Tissue homogenisation was carried out using a
Braun Micro Dismembrator (Braun, Melsungen, Germany.
Twenty-five milligram of tissue powder was extracted by a brief
vortex in 250ml RIPA buffer (50mM Tris, 150mM NaCl pH 7.4, 1%
NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulphate (SDS),
10mM EDTA, 2mM phenylmethylsulphonyl fluoride (PMSF) and
5m M N-ethylmaleimide (NEM)) followed by incubation at 41C for
1h on a rotisserie. All extracts were then centrifuged at 13000g for
15min. Supernatants were removed and the protein content of the
extracts determined using the bicinchoninic acid protein assay kit
(Pierce Chemical, Rockford, IL, USA) with bovine serum albumin
as the protein standard. Protein extracts were stored in aliquots at
 801C.
Forty microgram of protein was mixed with an equal volume of
SDS sample buffer, separated on a 10% SDS/polyacrylamide gel
and subsequently electroblotted onto a polyvinylidene difluoride
(PVDF) membrane (Bio-Rad, Hercules, CA, USA). Electroblotted
proteins were visualised via Ponceau Red staining. Human
fibulin-1 protein, isolated from human placenta by immunoaffinity
chromatography (Balbona et al, 1992), was used as a positive
control for immunoblotting. Electroblotted membranes were
blocked for 2h at RT in Tris-buffered saline (TBS) (50mM Tris,
150mM NaCl pH 7.6) containing 0.1% (vv
 1) Tween-20 and 5%
(wv
 1) nonfat dried milk (blocking solution B). The membranes
were washed briefly in TBS/0.1% Tween-20 and then probed
overnight at 41C with mouse antifibulin-1 mAb 3A11 diluted
1/1500 (1mgml
 1) in 5% blocking solution B. Following 3 10min
washes in TBS/0.1% Tween-20, membranes were incubated with
horseradish peroxidase-conjugated goat anti-mouse IgG (Promega,
Madison, WI, USA) diluted 1/2500 in 5% blocking solution for
30min at RT. After washing, immunoreactive complexes were
detected by enhanced chemiluminescence using ECL Plus (Amer-
sham Pharmacia Biotech, England) and recorded by exposure to
BioMax ML autoradiographic film (Eastman Kodak Company,
Rochester, NY, USA).
The PR status of the human breast cancer cell lines was
confirmed by immunoblot analysis. Probed membranes were
stripped and reprobed overnight at 41C with 1mgml
 1 mouse
anti-PR mAb (clone PR4-12) (Oncogene Research Products,
Cambridge, UK). Following detection, blots were again stripped
and reprobed for 1.5h at RT with the panspecific mouse antiactin
mAb (clone JLA20) (Oncogene), diluted 1/5000 in 5% blocking
solution B, to control for equal loading of protein. Bound
antibodies were detected as above.
Cells
Three ER/PR-positive human breast cancer cell lines (MCF-7,
T-47-D and BT-474) and three ER/PR-negative human breast
cancer cell lines (MDA-MB-231, HS-578-T and SK-BR-3) were used
in this study. All cell lines were obtained from the European
Collection of Cell Cultures (http://www.ecacc.org/). MCF-7 cells
were grown in minimal essential medium (MEM) (Sigma, Dorset,
UK) supplemented with 1% nonessential amino acids (Sigma). T-
47-D and MDA-MB-231 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (GIBCO BRL, Life Technologies, UK).
HS-578-T cells were grown in DMEM supplemented with
10mgml
 1 insulin (Sigma). BT-474 cells were grown in RPMI-
1640 (Sigma). SK-BR-3 cells were grown in McCoy’s 5a medium
modified (Sigma). All the above-mentioned cell culture medium
Table 1 Patient and histological data associated with tumor specimens
Characteristic n (%)
Patients
Total n 62 (100)
Normals 18 (29)
Benign tumours
Fibroadenomas 4 (6.5)
Phylloides 1 (1.6)
Breast Carcinomas
Primary tumours 36 (58.1)
Lymph node metatastasis 3 (4.8)
Carcinomas
Size (cm)
p2 6 (15.4)
>2 30 (76.9)
Unknown 3 (7.7)
Histological type
Ductal 27 (69.2)
Lobular 7 (18)
Unknown 5 (12.8)
Grade
1 2 (5.1)
2 10 (25.6)
3 20 (51.3)
Unknown 7 (18)
Nodal status
Negative 7 (18)
Positive 27 (69.2)
Unknown 5 (12.8)
ERa status
a
Positive 20 (51.3)
Negative 16 (41)
Unknown 3 (7.7)
PR status
b
Positive 15 (38.5)
Negative 21 (53.8)
Unknown 3 (7.7)
aERa=oestrogen receptor alpha.
bPR=progesterone receptor.
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ytypes were supplemented with 10% foetal calf serum (FCS), 2mM
L-glutamine, penicillin (100unitsml
 1) and streptomycin
(100mgml
 1) (GIBCO). Cells were maintained at 371Ci n5 %C O 2
at 100% humidity. At 5 to 7 day intervals, cells were passaged using
trypsin–EDTA (GIBCO).
Effect of oestrogen on fibulin-1 processing by cultured
cells
Steroids were depleted from heat-inactivated FCS with dextran-
coated-activated charcoal (DCC) (Sigma) (Devleeschouwer et al,
1987). Cells were grown for 5 days in phenol red-free medium
containing 10% DCC-treated FCS. Cells were then washed with
phenol red-free medium and treated for 48h with either 10nM
oestradiol, or ethanol vehicle in phenol red-free medium minus
serum. After 48h, the conditioned culture medium (CCM) was
removed and both PMSF and NEM added to 2 and 5mM final
concentration, respectively. Cell debris was removed by centrifuga-
tion. The supernatant was then concentrated using Centricon YM-30
filters (Millipore, Malborough, MA, USA) for 1h at 3000g.T h e
protein content of the concentrated CCM was determined as
described above. The remaining cell layer was washed twice with
ice-cold PBS and extracted using RIPA buffer supplemented with
10mM EDTA. The extract was then centrifuged at 13000g for 15min
at 41C. The supernatant was removed and protein concentration of
the extract determined. Forty microgram aliquots of protein were
evaluated by immunoblot analysis as described above.
Quantification and statistical analysis
Radiographs from immunoblot experiments were scanned and
densitometric analysis performed using a GDS 8000 system,
together with Gel Works 1D analysis software (Ultra-Violet
Products Ltd, Cambridge, England). Nonspecific background was
subtracted and band intensity values derived. Comparisons
between unpaired groups were performed using the nonparametric
Mann–Whitney U-test. Associations between either fibulin-1
expression or processing and clinicopathological parameters were
examined using the Spearman rank correlation test or with
dichotomised variables using the w
2 test of independence. All
reported P-values refer to a two-sided test of significance. P-values
p0.05 were considered to be significant.
RESULTS
Fibulin-1 protein expression in human breast cancers
and normal breast tissue
Fibulin-1 protein expression was examined immunohistochemi-
cally in human breast tissue using a mouse anti-human fibulin-1
mAb (clone 3A11). The 3A11 antibody reacts with an epitope
located at the N-terminus of fibulin-1 and detects all four
documented splice variants of the protein (Argraves et al, 1990).
In normal breast tissue, fibulin-1 protein expression predominated
in the ductal epithelium and underlying myoepithelium, with
weaker staining evident in the loose connective tissue (L-CT)
surrounding the ducts (Figure 1A). Examination of ductal
carcinoma in situ (Figure 1B) and invasive breast carcinomas
(Figure 1C) revealed that tumour cells expressed fibulin-1 protein,
with the connective tissue surrounding these tumour cells also
exhibiting moderate expression of fibulin-1.
Fibulin-1 protein expression was semiquantitatively assessed in
a range of breast carcinoma and normal breast tissue biopsies
by densitometric analysis of immunoblots. Purified fibulin-1
protein, derived from human placenta, was used as a positive
control. Under reducing conditions, the 3A11 mAb specifically
recognised the 100kDa placenta-derived fibulin-1 protein
(Figure 2A, lanes 1 and 13). In detergent extracts from breast
tissue (Figure 2A, lanes 2–12), three major immunoreactive bands
were detected, one of which corresponds to the 100kDa mature
fibulin-1 polypeptide, with two additional bands at 55 and 50kDa.
These smaller fragments represent processed forms of fibulin-1,
A
C
DE L-CT
B
Figure 1 Fibulin-1 protein expression in normal breast tissue and
invasive ductal carcinoma. Paraffin-embedded tissue sections of normal
breast tissue (A), ductal carcinoma in situ (B) and invasive ductal carcinoma
(C) were stained with antifibulin-1 3A11 mAb (brown). In (A),
immunostaining is prominent in the epithelial layer of the duct (DE), with
weaker staining apparent within the L-CT surrounding the ducts. In (B), the
carcinoma cells of solid-type ductal carcinoma in situ stained markedly with
antifibulin-1 antibody (arrow). In (C), fibulin-1 protein expression is
apparent in the invasive ductal carcinoma cells (extended arrows). Sections
were counterstained with methyl green. Bars indicate 20mm. Immunostain-
ing specificity was checked using an irrelevant mouse mAb of the same IgG
subclass (data not shown).
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ymost likely generated by proteolysis of the full-length fibulin-1
polypeptide.
A comparison of 100kDa fibulin-1 expression in normal breast
tissue, benign tumours and breast carcinomas is shown in Figure 3.
Fibulin-1 protein expression was significantly increased in breast
carcinomas as compared to normal breast tissue (Mann–Whitney
U-test, P¼0.0005). An increase in fibulin-1 protein expression was
also observed in the breast carcinomas compared to benign
tumours, but this difference did not reach significance (Mann–
Whitney U-test, P¼0.2), probably owing to the low number of
benign tumours examined. Regarding 100kDa fibulin-1 expres-
sion, no significant difference was observed between normal breast
tissue and benign tumours (Mann–Whitney U-test, P¼0.3). The
55kDa immunoreactive fragment was equally detected in both
normal and carcinoma breast tissue (Figure 2). However, the
50kDa fragment was found more frequently in benign breast
tumours (five out of five, 100%) (w
2¼4.55, P¼0.03) and in breast
carcinomas (35 out of 39, 90%) (w
2¼17.22, Po0.0001) than in
normal breast tissue (six out of 18, 33%). In summary, these results
provide evidence for elevated expression and altered processing of
fibulin-1 protein in breast tumour development and progression.
Association of fibulin-1 expression with prognostic
variables
Full-length fibulin-1 protein is known to be secreted by oestrogen-
responsive ovarian cancer cells upon exposure to oestradiol
(Clinton et al, 1996). In addition, fibulin-1 expression was
previously shown to be inversely correlated with PR protein levels
in ovarian carcinomas (Roger et al, 1998). However, expression of
100kDa fibulin-1 in the breast carcinomas examined here did not
correlate with either ERa or PR status (Table 2). Previous studies
have suggested benefits in viewing ERa and PR levels as
continuous rather than dichotomous variables (Chapman et al,
1996). Therefore, we examined the relation of fibulin-1 expression
with ERa and PR protein concentrations using the Spearman rank
correlation test. Accordingly, fibulin-1 protein expression was
inversely correlated with ERa protein concentration (rs¼ 0.34,
Po0.04, n¼36), but not with PR levels (rs¼ 0.18, P¼0.3,
n¼36) (Figure 5A and B).
When viewed as the ratio of the 50kDa fragment to the mature
fibulin-1 polypeptide, fibulin-1 processing was more extensive in
ERa-positive as compared to ERa-negative breast carcinomas
(P o 0.05, n¼36) (Figures 2 and 4). A positive correlation was
also found between fibulin-1 processing and absolute ERa protein
concentration (rs¼0.49, Po0.003, n¼36) (Figure 5C). A similar
correlation with fibulin-1 processing was observed with PR protein
concentration (rs¼0.43, P¼0.008, n¼36) (Figure 5D). As shown
in Table 2, fibulin-1 protein expression and processing did not
correlate with any other prognostic variables, including tumour
size, histological type, tumour stage or lymph node involvement.
Fibulin-1 processing in human breast tumour-derived cells
As processing was associated with both ERa and PR in human
breast carcinomas, we next studied the relation of fibulin-1
processing in vitro using three ER/PR-positive (MCF-7, T47D and
BT-474) and three ER/PR-negative (MDA-MB-231, HS-578-T and
SK-BR-3) human breast tumour-derived cell lines. Immunoblot
analysis of fibulin-1 was performed on both cell extracts and CCM
(Figure 6). Full-length fibulin-1 protein was detected in the CCM
(Figure 6A), but not in the cell extract (Figure 6B) of the six human
breast tumour-derived cell lines analysed. The 50kDa fragment
was detected at different levels in the various cell extracts
examined, with lower amounts being expressed in two ER/PR-
negative breast cancer cell lines (MDA-MB-231 and HS-578-T). An
additional 26kDa fragment was detected in the three ER/PR-
positive cell lines (Figure 6B). The 26kDa fragment was also
detected in two out of 36 (5.5%) of the breast carcinomas (data not
shown). Notably, this subset of carcinomas expressed strikingly
high levels of both ERa and PR. The 50kDa fragment may
represent an intermediate product, which can be further processed
into a 26kDa fragment. Alternatively, the 26kDa fragment may be
directly derived from the mature 100kDa fibulin-1 polypeptide via
degradation. The absence of the 55kDa fragment in any of the
breast tumour cell lines examined may be reflective of a stromal
origin for this fragment in breast tissue. Overall, fibulin-1
processing was more extensive in the ER/PR-positive as compared
to ER/PR-negative breast tumour cell lines.
Fibulin-1 processing is not regulated by oestrogen in
T47D breast tumour cells
We then examined the effect of oestrogen on fibulin-1 processing
in the ER/PR-positive T47D cell line. Cells were deprived of
steroids by culturing for 5 days in 10% DCC-FCS phenol red-free
DMEM. Both the rate of cell proliferation and levels of oestrogen-
inducible proteins, such as the PR, are significantly reduced when
the cells are cultured in serum pretreated with dextran charcoal
(Hurd et al, 1999; Iwasaki et al, 1999). The charcoal treatment is
Normal Tumour
ERα
A
B
100 kDa
50 kDa
Lane no.
55 kDa
12 34 5 6 789 1 0 1 1 1 2 1 3
++ + - --
Figure 2 Analysis of fibulin-1 protein expression in representative breast
tissue extracts. In (A), purified human fibulin-1 protein (lanes 1 and 13) and
40mg of breast tumour extracts (lanes 2–7) and 40mg of normal breast
tissue (lanes 8–12) extract. Samples were run on a 10% polyacrylamide gel
under reducing conditions, transferred to PVDF membrane and probed
with the 3A11 mAb, which is directed against the N-terminus of human
fibulin-1. In addition to the mature fibulin-1 polypeptide (apparent
molecular mass of 100kDa) immunoreactive fragments of 55 and 50kDa
are detectable. The ER status of the breast tumours is also indicated. In (B),
the blot shown in (A) was stripped and reprobed with a panspecific
antiactin antibody to serve as a control for protein loading.
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Figure 3 Comparison of full-length fibulin-1 protein expression in
normal breast tissues (n¼18), benign tumours (n¼5) and breast
carcinomas (n¼39). Levels of 100kDa fibulin-1 were quantified by
densitometric analysis and expressed in arbitrary units. Bar, median value. P-
values were determined according to the nonparametric Mann–Whitney
U-test for unpaired values. Full-length fibulin-1 protein was significantly
elevated in the breast carcinoma specimens as compared to normal breast
(P¼0.0005).
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As shown in Figure 7B, the level of PR is significantly reduced
when the cells are grown for 5 days in stripped serum (lane 3; C
stripped) compared with cells grown in control whole serum (lane
2; C whole). Exposure of the cells to 10nM oestradiol for 48h
reverses this effect (lane 4), indicating reactivation of the ER
pathway. However, alteration in ER function via either steroid
depletion or re-exposure to oestrogen did not affect fibulin-1
processing (Figure 7A). Similarly, the level of fibulin-1 secreted
into the medium from T47D cells was not altered in response to
oestrogen stimulation (Figure 8).
DISCUSSION
The present investigation demonstrates that elevated fibulin-1
protein expression is associated with breast cancer. This work is in
agreement with a recent study showing increased expression of
fibulin-1 mRNA in a small panel of breast carcinoma specimens as
compared to normal breast tissue (Forti et al, 2002). In our study,
fibulin-1 protein was detected via immunhistochemistry in both
the stromal and epithelial compartments of normal and neoplastic
breast tissue. In addition, we observed no significant alteration in
the expression of the 55kDa processed form of fibulin-1 between
normal- and tumour-derived breast tissue. Thus, it is unlikely that
the increase in the expression of full-length fibulin-1 protein in
breast carcinoma is due primarily to an increase in the ratio of
epithelial cells. This issue may be resolved in future studies
examining the expression of fibulin-1 in specific cellular compart-
ments isolated by microdissection. In the case of ovarian cancer,
while fibulin-1 mRNA is produced by tumour-derived epithelial
cells, fibulin-1 protein has been shown to accumulate in stroma
surrounding the tumour cells (Roger et al, 1998). Given that the
same mAb was used in both studies, it may be concluded that
fibulin-1 protein accumulates in different compartments in a
context-specific manner.
A number of other ECM proteins display modulated expression
in association with cancer. For example, fibronectin and tenascin
Table 2 Relationship between prognostic variables and fibulin-1 expression and processing
Clinical characteristics n
a Fibulin-1 expression
b P
c Fibulin-1 processing
d P
e
Tumour size
p2cm 6 15 19.9
>2cm 30 19.2 0.4 18.2 0.7
Unknown 3
Histological type
Ductal 27 16.5 17.6
Lobular 7 21.3 0.3 17.1 0.9
Unknown 5
Histological grading
G1,G2 12 16.8 13.3
G3 20 16.3 0.9 18.4 0.1
Unknown 7
Nodal status
Negative 7 19.3 12.7
Positive 20 16.4 0.5 18.7 0.2
Unknown 12
ERa status
f
Positive 20 15.9 21.7
Negative 16 21.8 0.09 14.6 0.045
Unknown 3
PR status
g
Positive 15 16.9 21.6
Negative 21 19.6 0.4 16.6 0.2
Unknown 3
an, number of breast carcinomas including 36 primary breast carcinomas and three lymph node metastases.
bLevel
of full-length (100kDa) fibulin-1 polypeptide as determined by densitometric analyses of immunoblots (represented
in arbitrary units).
c,eP-values were calculated using a nonparametric Mann–Whitney U-test for comparison of
means.
dFibulin-1 processing was determined as the ratio of the 50kDa fragment to the mature form (i.e. 50/
100kDa).
fERa=oestrogen receptor alpha.
gPR=progesterone receptor.
0
5
10
15
0.95
2.5
P < 0.05
ERα-negative                 ERα-positive
Fibulin-1 processing  (50 kDa/100 kDa)
Figure 4 Relationship between fibulin-1 processing and ER status. Levels
of 100kDa fibulin-1 and the 50kDa processed fragment were quantified by
densitometric analysis of immunoblots. The resulting arbitrary units were
used to determine the extent of fibulin-1 processing (expressed as the ratio
of the 50kDa fragment to the full-length polypeptide). Bar, median value. P-
values were determined according to the nonparametric Mann–Whitney
U-test for unpaired values. The extent of fibulin-1 processing (50/100kDa)
was significantly higher in ERa-positive than in ERa-negative breast
carcinomas (Po0.05).
Fibulin-I in human breast cancer
LM Greene et al
875
British Journal of Cancer (2003) 88(6), 871–878 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yare upregulated in breast cancer (Mackie et al, 1987; Loridon-Rosa
et al, 1988; Koukoulis et al, 1993; Ishihara et al, 1995; Takei et al,
1995, 1998; Jahkola et al, 1996), while laminin-5 expression is
increased in gliomas, gastic carcinomas, and squamous carcino-
mas, but downregulated in prostate and breast carcinomas (Martin
et al, 1988). At least one common denominator between these
proteins is that they each influence cell adhesion and migration
(Akiyama et al, 1995; Giese et al, 1996; Romberger, 1997;
Greenwood and Murphy-Ullrich, 1998; Hirosaki et al, 2000; Twal
et al, 2001). Fibulin-1 has been shown to suppress the adhesion
and motility of a number of tumour cell lines, including the breast
carcinoma cell line MDA-MB-231. The elevated expression of
fibulin-1 protein seen in breast and ovarian carcinomas (Clinton
et al, 1996) may be reflective of a similar role in vivo. The recent
observation that ovarian carcinomas exhibit an increased ratio of
fibulin-1C:1D mRNA (Moll et al, 2002) suggests that these fibulin-
1 variants exhibit differing functions. It is tempting to propose that
the balance of fibulin-1 variant expression is an important
determinant of whether the expressed fibulin-1 displays tumour-
suppressive or oncogenic activities.
In addition to elevated expression of the full-length (100kDa)
fibulin-1 polypeptide in breast carcinomas vs normal breast tissue,
we also observed differential production of additional fibulin-1
immunoreactive fragments. The exact origin of these N-terminal
fragments is still unclear, but the most likely mechanism of
generation is via proteolysis of the mature fibulin-1 polypeptide.
Indeed, fibulin-1 proteolysis has already been described in vitro
(Sasaki et al, 1996) and in studies of cultured skin fibroblastic
cells (Debeer et al, 2002), as well as in the skin of mice exhibiting
2,4-dinitrofluorobenzene-induced chronic contact dermatitis
(Kusubata et al, 1999). Other explanations for the origin of the
N-terminal fibulin-1 fragments include differential alternative
splicing and/or the usage of internal ribosome entry sites.
In this study, we indicate that altered fibulin-1 processing is
associated with breast cancer. Specifically, a 50kDa N-terminal
fragment of fibulin-1 was detected more frequently in breast
carcinomas as compared to normal breast tissue. Moreover, an
increased ratio of the 50kDa fragment to the mature fibulin-1
polypeptide was observed in ERa-positive breast carcinomas as
compared to ERa-negative carcinomas. Assuming that the
observed immunoreactive polypeptides correspond to proteolytic
fragments of fibulin-1, our results indicate that altered proteolysis
of fibulin-1 is also associated with breast cancer. The
55kDa fragment of fibulin-1 detected in both normal and breast
cancer tissues may represent a precursor form, which is
further digested to the 50kDa fragment. On the other
hand, it may represent a phosphorylated version of the 50kDa
fragment.
Additionally, the 26kDa fragment was only detectable in ERa-
positive breast carcinomas and ERa-positive breast cancer-
derived cell lines. Digestion of mouse fibulin-1 protein with
human leukocyte elastase produces an N-terminal fragment of
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Figure 5 Relationship between fibulin-1 expression (A, B) or processing (C, D) and ERa (A, C) and PR (B, D) protein concentration. Fibulin-1
expression and processing was determined as in Figures 3 and 4, respectively. The ERa and PR concentrations were determined by cytosolic assays. There
was a significant inverse correlation between fibulin-1 expression and ERa protein concentration (rs¼ 0.34, Po0.04, n¼36; the Spearman rank
correlation). In addition, the correlation between fibulin-1 processing and ERa (rs¼0.49, Po0.003) and PR receptor (rs¼0.43, Po0.008) status was highly
significant.
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to the immunoreactive fragment observed in this study. Intrigu-
ingly, elastases are also elevated in breast cancer (Kao and Stern,
1986). Furthermore, proteinase-like peptidase activities were
previously found to be higher in patients with steroid receptor-
rich breast tumours than in receptor-poor tumours (Vasishta et al,
1989). If the observed fragments are derived by proteolysis of
mature fibulin-1 polypeptide, it is reasonable to hypothesise that
the altered processing of fibulin-1 is reflective of differential
proteinase activity in the breast tumours.
Fibulin-1C mRNA expression can be induced by oestrogen in
ERa-positive ovarian tumour cell lines (Clinton et al, 1996);
however, its association with ERa status in ovarian cancers is still
unclear (Clinton et al, 1996; Moll et al, 2002). Interestingly, we
found an inverse relation between the levels of full-length fibulin-1
protein and ERa protein concentration in breast cancers. We also
found no evidence for augmented secretion of fibulin-1 by ERa-
positive T47D breast cancer cells treated with oestrogen. While
fibulin-1C and -1D variants differ at the C-terminus, both yield
similar sized mature polypeptides as determined by immunoblot
analysis. Indeed, currently available antibodies are still not capable
of determining which fibulin-1 variant is predominantly expressed.
It remains to be seen as to whether hormonal regulation of fibulin-
1 expression is variant-specific.
In conclusion, our results have shown that fibulin-1 protein is
elevated in human breast carcinomas as compared to normal
breast tissue. Upregulation of fibulin-1 protein may be useful as a
marker for breast and ovarian cancer. Clearly, additional
investigations are required to determine if enhanced fibulin-1
protein expression is associated with other tumour types and if
such altered expression is variant-specific. Also, further analysis
will be required to determine if the processed fragments of fibulin-
1 retain biological activity.
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